The Drug Enforcement Administration placed Epidiolex in Schedule V, marking the first time any drug derived from any part of the cannabis plant has been rescheduled in the U.S.

“Marijuana extracts,” including CBD, remain in Schedule I, according to the administration’s 2016 Final Rule.

According to the DEA, “Schedule V drugs, substances, or chemicals are defined as drugs with lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics.”

See the original article from Cannabis Business Times